Cue Biopharma
CUE
90 hedge funds and large institutions have $186M invested in Cue Biopharma in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 13 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 26
34% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $1.11M
1% more funds holding
Funds holding: 89 → 90 (+1)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0.06% less ownership
Funds ownership: 1.79% → 1.73% (-0.06%)
24% less capital invested
Capital invested by funds: $246M → $186M (-$59.8M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.57M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.59M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$2.24M |
| 4 |
BlackRock
New York
|
+$1.67M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$13.8M |
| 2 |
6CM
683 Capital Management
New York
|
-$10.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.15M |
| 4 |
Morgan Stanley
New York
|
-$3.83M |
| 5 |
Goldman Sachs
New York
|
-$1.06M |
CUE Hedge Fund Activity: Q4 2021 in Review
90 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2021, worth a combined $186M — down 24% from $246M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CUE positions and 13 closed out — a net gain of 1 holder — while 35 added to existing stakes and 26 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $8.57M. The largest seller was Corriente Advisors, exiting entirely with an estimated $13.8M sold.
- 90 institutional investors held Cue Biopharma (CUE) as of Q4 2021, up from 89 in Q3 2021.
- Funds reported $186M of Cue Biopharma stock for Q4 2021, down 24% quarter-over-quarter.
- 14 funds opened new Cue Biopharma positions in Q4 2021 and 13 closed out, a net change of +1 holder.
- The largest Cue Biopharma buyer in Q4 2021 was Dimensional Fund Advisors, an estimated $8.57M added.
- The largest Cue Biopharma seller in Q4 2021 was Corriente Advisors, an estimated $13.8M sold.
Based on aggregated 13F filings for Q4 2021.